Heart Failure

The AJMC® Heart Failure compendium is a comprehensive resource for clinical news and expert insights for the chronic condition in which the heart doesn't pump enough blood due to damaged heart muscle.

Latest News

Doctor writing prescription | Image credit: 18percentgrey – stock.adobe.com
SGLT2i Prescriptions for Heart Failure Are Rising, but Vary Across US

November 18th 2024

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half of their patients.

Liver and stethoscope | Image credit: filins – stock.adobe.com
Liver Fibrosis Scores May Hint at Heart Failure Risk

November 13th 2024

Man having heart attack | Image credit: JU.STOCKER – stock.adobe.com
β-Blockers May Raise Depression Risk for Heart Attack Survivors Without Heart Failure

November 13th 2024

Doctor holding stethoscope to red heart | Image credit: lenets_tan – stock.adobe.com
How the Clinical Trial Gender Gap Affects Women’s Heart Care

October 18th 2024

Woman at heart doctor | Image credit: Seventyfour – stock.adobe.com
Why Are We Still Seeing Gaps in Women’s Heart Care?

October 15th 2024

Heart Failure Clinical and Economic Burden

An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease.

John McMurray screenshot
Continuing Medical Education
View All
November 23rd 2024

Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction

1.0 Credits / Cardiology
November 23rd 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
November 23rd 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Cardiovascular Disease Improvements Seen Among Individuals With Type 2 Diabetes, Study Shows
April 30th 2020

Cardiovascular Disease Improvements Seen Among Individuals With Type 2 Diabetes, Study Shows

Maggie L. Shaw
The risk of both heart attack and stroke increases 2- to 3-fold among individuals with comorbid diabetes and cardiovascular issues; however, recent study results show improved odds of both not occurring, as well as less of a risk of hospitalization for heart failure or lower extremity amputation.
Do Caregivers for Patients With Heart Failure Benefit From Telehealth?
April 23rd 2020

Do Caregivers for Patients With Heart Failure Benefit From Telehealth?

Maggie L. Shaw
In the United States, heart failure affects a patient population of over 6.5 million. Through medication management, transportation, and emotional support, among the many tasks they assist with, these patients’ caregivers provide services valued at $7.9 billion annually.
Multidimensional Assessments Better Gauge Frailty in Patients With Heart Failure
April 19th 2020

Multidimensional Assessments Better Gauge Frailty in Patients With Heart Failure

Jared Kaltwasser
As more patients with heart disease live longer, physicians need better tools to assess frailty in those with heart failure. New study results suggest a multidimensional assessment approach is preferable to one that focuses only on physical metrics.
Caution Strongly Recommended When Using Chloroquine, Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19
April 17th 2020

Caution Strongly Recommended When Using Chloroquine, Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19

Maggie L. Shaw
Despite positive results seen from the use of chloroquine and hydroxychloroquine in some patients hospitalized with coronavirus disease 2019 (COVID-19), concern is mounting about how these drugs affect patients’ cardiovascular health, specifically the heart.
Are Current Blood Iron Levels Appropriate for Use in Patients With Heart Failure?
April 15th 2020

Are Current Blood Iron Levels Appropriate for Use in Patients With Heart Failure?

Maggie L. Shaw
The chemical symbol for iron is Fe, which stems from the Latin word for iron, Ferrum. Therefore, it is easy to see the connection on how ferritin is the protein responsible for iron storage and release in the body and transferrin is the protein responsible for transporting that iron.
Minority, Female, and Older Patients Remain Underrepresented in ACS Clinical Trials
April 10th 2020

Minority, Female, and Older Patients Remain Underrepresented in ACS Clinical Trials

Maggie L. Shaw
Does patient representation in trials of acute coronary syndrome (ACS) correlate with epidemiologic studies of patients with the condition? According to recent results published in JAMA Cardiology, older patients, women, and black patients continue to be underrepresented in ACS trials.
Heart Failure Plus Pollution Appears to Increase Dementia Risk, Study Indicates
April 8th 2020

Heart Failure Plus Pollution Appears to Increase Dementia Risk, Study Indicates

Maggie L. Shaw
Almost 70% of the world’s population could be living in urban areas, being continuously exposed to air pollution, by 2050, while cases of dementia are expected to triple. Recent study results highlight the link between cardiovascular disease and dementia, as mediated by long-term exposure to air pollution.
Late-Stage Trial for Dapagliflozin Ends Early After Showing Efficacy for Chronic Kidney Disease
March 30th 2020

Late-Stage Trial for Dapagliflozin Ends Early After Showing Efficacy for Chronic Kidney Disease

Allison Inserro
Dapagliflozin is currently indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D). In the United States, it is also approved to reduce the risk of hospitalization for heart failure in patients with T2D and established cardiovascular (CV) disease or multiple CV risk factors.
Possible Link Found Between Early Heart Failure and Pregnancy Complications
March 28th 2020

Possible Link Found Between Early Heart Failure and Pregnancy Complications

Maggie L. Shaw
Pregnancy complications that include preeclampsia, gestational hypertension, pre-term birth, and low birthweight serve as possible indicators for greater risk of heart failure in the long term, as indicated by change in global longitudinal strain on echocardiogram.
Mortality, Risk Factors of Patients With Cardiac Injury and COVID-19
March 25th 2020

Mortality, Risk Factors of Patients With Cardiac Injury and COVID-19

Maggie L. Shaw
Evidence is considered lacking on the association between mortality and patients who have both cardiac injury and coronavirus disease 2019 (COVID-19). Is the rate of death higher among these patients compared with patients without cardiac disease who have COVID-19?
Clinical Variable Model More Reliable at Predicting Mortality Among Veterans
March 22nd 2020

Clinical Variable Model More Reliable at Predicting Mortality Among Veterans

Maggie L. Shaw
Are coding changes responsible for declines in the 30-day mortality rate for hospital admissions among veterans utilizing Veterans Health Administration medical centers? Which model is more accurate at predicting this measure: a claims-based model or a clinical factor–based model?
Palliative Care Is Underutilized for Patients With Heart Failure
March 20th 2020

Palliative Care Is Underutilized for Patients With Heart Failure

Maggie L. Shaw
By 2030, heart failure—which tops the list of reasons for hospitalization among individuals older than 65 years—could tax the healthcare system $69.8 billion each year. Study results show the success of palliative care at reducing both healthcare costs and hospitalization.
How Vulnerable Are Patients With Cardiovascular Disease to COVID-19, Flu Complications?
March 12th 2020

How Vulnerable Are Patients With Cardiovascular Disease to COVID-19, Flu Complications?

Maggie L. Shaw
Patients with cardiovascular disease are especially vulnerable to respiratory infections, although uncertainty remains on just what damage COVID-19 can cause in these patients. The flu season is also in full swing, with an estimated 440,000 individuals hospitalized so far in the United States alone, according to the CDC.
Wearable Sensor May Help Reduce Subsequent Heart Failure Hospitalization, Costs
March 4th 2020

Wearable Sensor May Help Reduce Subsequent Heart Failure Hospitalization, Costs

Maggie L. Shaw
Eighty percent of annual costs for heart failure come from hospitalization for the condition, which more than 23 million persons suffer from worldwide, 6.2 million (27%) in the United States alone. These costs are estimated to increase almost 58% between 2012 and 2030, from $30.7 billion to $53 billion.
Bringing a Precision Medicine Approach to Heart Failure
February 29th 2020

Bringing a Precision Medicine Approach to Heart Failure

Mary Caffrey
Barriers to better treatment start with the basic definitions of heart failure. Classifications in use for decades, such as the New York Heart Association system or the left ventricle ejection fraction measure, need an overhaul, and the field should take a precision medicine approach that brings analytics and biomarkers to the cause.
Canagliflozin Conveys Lower Risk of Adverse CV Events in Patients With High CV Risk, T2D
February 27th 2020

Canagliflozin Conveys Lower Risk of Adverse CV Events in Patients With High CV Risk, T2D

Maggie L. Shaw
Updated results from the EASEL study show that lower risks of cardiovascular (CV) events, CV death, and CV mortality accompany initiation of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes (T2D) and high CV risk compared with use of other drugs.
Sudden Cardiac Death, Heart Disease Surprise More Women Than Men
February 21st 2020

Sudden Cardiac Death, Heart Disease Surprise More Women Than Men

Maggie L. Shaw
Circulation, a peer-reviewed journal of the American Heart Association, just released its fourth annual Go Red for Women issue, in which researchers from the Smidt Heart Institute at Cedars-Sinai note the stark disparities in how heart disease manifests in women and men. For women, sudden cardiac death is often the first sign they even have heart disease.
What Other Condition Might Dapagliflozin Prevent? How About Afib?
February 14th 2020

What Other Condition Might Dapagliflozin Prevent? How About Afib?

Mary Caffrey
Competing trials are under way that may show that the benefits of SGLT2 inhibitors in heart failure are a class effect.
Heart Disease and Smoking Are Locked in an Ongoing Battle Against Patient Health
February 11th 2020

Heart Disease and Smoking Are Locked in an Ongoing Battle Against Patient Health

Maggie L. Shaw
There are more than 36 million smokers in the United States today, and most (70%) admit they want to quit. Individuals who decide to quit see a smaller risk of heart disease within 1 to 2 years, along with reduced risks of stroke and peripheral vascular disease. However, annual deaths from smoking still exceed 480,000 in the United States, where over 16 million live with smoking-related diseases that include infertility, lung cancer, and chronic obstructive pulmonary disease.
Dr Roland Chen: BMS, Pfizer Committed to Improving Care for Patients With Atrial Fibrillation
February 10th 2020

Dr Roland Chen: BMS, Pfizer Committed to Improving Care for Patients With Atrial Fibrillation

GUARD-AF is an example of the commitment of the BMS, Pfizer Alliance in trying to further the standard of care in patients with atrial fibrillation, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.
Are Prognostic Models Accurate at Predicting Mortality, Morbidity in Patients With Chronic Heart Failure?
February 8th 2020

Are Prognostic Models Accurate at Predicting Mortality, Morbidity in Patients With Chronic Heart Failure?

Maggie L. Shaw
In 2017, heart failure contributed to 1 in 8 deaths. This inability of the heart to function at its optimal level led to an estimated $30.7 billion in annual healthcare costs in 2012, including healthcare services, medicines, and missed work.
Deeper Dive Into Rosiglitazone Data Reveals Link to CV Risk, Especially Heart Failure
February 6th 2020

Deeper Dive Into Rosiglitazone Data Reveals Link to CV Risk, Especially Heart Failure

Mary Caffrey
The most detailed look ever at data for rosiglitazone, the diabetes drug marketed by GlaxoSmithKline (GSK) as Avandia, shows the one-time blockbuster significantly raises the overall risk of heart problems or cardiovascular death, calling attention to the need for more transparency in data collection.
Dr Javed Butler: Recognizing Risk of Heart Failure in Patients With Diabetes Key to Preventive Care
February 1st 2020

Dr Javed Butler: Recognizing Risk of Heart Failure in Patients With Diabetes Key to Preventive Care

Improving recognition of the link between heart failure and diabetes can promote preventive care for at-risk patients, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi.
Shock Only or Drug-Shock? 2 Different Cardioversion Techniques Equally Effective, Study Says
January 31st 2020

Shock Only or Drug-Shock? 2 Different Cardioversion Techniques Equally Effective, Study Says

Allison Inserro
The drug-shock strategy was more effective for patients experiencing atrial fibrillation for the first time and for patients younger than 70 years, the researchers said.
Are Transitional Care Services Worth Investing In for Heart Failure?
January 28th 2020

Are Transitional Care Services Worth Investing In for Heart Failure?

Maggie L. Shaw
Heart failure (HF) taxes the American healthcare system by a total of $39.2 billion to $60 billion each year. This amount is expected to increase up to 20% by 2030 and total $70 billion. Worldwide, HF has been diagnosed in 26 million individuals, and this number is rising.
Experiments Give Insights Into Dapagliflozin's Cardioprotective Effects
January 25th 2020

Experiments Give Insights Into Dapagliflozin's Cardioprotective Effects

Mary Caffrey
The authors write that the drug's apparent cardioprotective effects in the angiotensin II stressed mice—the decreased fibrosis, reduced inflammation and oxidative stress—all merit further study.
Does Excess Body Weight Equal Adverse Heart Health Outcomes?
January 20th 2020

Does Excess Body Weight Equal Adverse Heart Health Outcomes?

Maggie L. Shaw
Hypertrophic cardiomyopathy is an abnormal thickening of the heart muscle, with causes that include genetic mutations and myofiber disarray (an abnormal heart muscle cell arrangement). Individuals who have this condition are prone to obesity (body mass index, 25 to
Dr Javed Butler on Importance of Diabetes Can Break Your Heart Initiative for American Heart Month
January 19th 2020

Dr Javed Butler on Importance of Diabetes Can Break Your Heart Initiative for American Heart Month

Diabetes Can Break Your Heart is an important initiative that highlights the vital need for heightened education on the link between diabetes and heart failure, especially with American Heart Month looming, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi.
What We're Reading: Improvements in Health Disparities Stall; Reanimating Hearts; Aging Population Concerns
January 16th 2020

What We're Reading: Improvements in Health Disparities Stall; Reanimating Hearts; Aging Population Concerns

AJMC Staff
Since 2016, racial and ethnic healthcare disparities have not improved; a new method of "reanimating" hearts from recently deceased donors for transplants is being tested; the new decade prompts concerns about an aging population.
Risk of Heart Disease Among Childhood Cancer Survivors Falls Since 1970s, Data Show
January 16th 2020

Risk of Heart Disease Among Childhood Cancer Survivors Falls Since 1970s, Data Show

Mary Caffrey
While the number of survivors who had cardiotoxic treatments increased, the doses they received decreased. Radiation exposure fell from 77% in the 1970s to 40% in the 1990s.
<1
...
101112131415161718
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo